Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Randomized, Placebo-controlled, Double-blind, Cross-over Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With Cystic Fibrosis

NCT03925194 is registered in ClinicalTrials.gov with Heidelberg University as lead sponsor.

NCT NCT03925194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03925194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Randomized, Placebo-controlled, Double-blind, Cross-over Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With Cystic Fibrosis
Lead sponsor
Heidelberg University
Phase
Phase 2
Overall status
Terminated
Start date
December 1, 2022
Completion date
July 25, 2025
Enrollment
33 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis, 10011762